Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…Ambulosono: A Novel Sensor-based System for Quantitative Evaluation Freezing of Gait in Parkinson’s disease
Objective: We prospectively evaluated the manifestations of On-Drug freezing of gait (FOG) of Parkinson’s disease (PD) in China using a novel sensor-based system. Background: FOG…Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model
Objective: To clarity the effects and mechanism of poly-ADP-ribose polymerase 1(PARP1) in regulating mitochondrial fusion/fission in a rotenone-induced Parkinson's disease (PD) model. Background: Accumulating evidences…Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study
Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…Beta-adrenoreceptor medications and risk of Parkinson’s disease
Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation
Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…Cardiac Autonomic Dysfunction in Patients with Multiple System Atrophy: A cross-sectional study
Objective: The study aimed to assess cardiac autonomic dysfunction in patients with multiple system atrophy (MSA). Background: MSA is a progressive neurodegenerative disorder with predominant…
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 149
- Next Page »